Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in the treatment and prevention of relapse/recurrence of non-infectious intermediate, posterior or pan-uveitis (LINNAEA)

Next Previous
X
Search
Trial Profile

A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in the treatment and prevention of relapse/recurrence of non-infectious intermediate, posterior or pan-uveitis (LINNAEA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izokibep (Primary) ; Prednisolone; Prednisone
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LINNAEA
  • Sponsors ACELYRIN; Affibody

    • Most Recent Events

    • 03 May 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
    • 30 Jan 2023 Status changed from active, no longer recruiting to completed.
    • 18 Jul 2022 Planned End Date changed from 1 Dec 2023 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top